Carefully Does It
19 Oct 2016
Re: '...materially below... It is interesting Blanket.Certainly potential but the net debt is a real concern and it makes sense for that to be addressed and doing so might result in dilution. Thoughts?What else are they likely to do to reduce the debt drag?Convertible loan note?Sell something?
Carefully Does It
19 Oct 2016
Unlikely but not impossible - fund raising What chance of a funding round given it is profitable but net debt a substantial drag to future growth once NuPharm is closed?'A lower level of net debt would help to support the further growth of the refocused business'Draw a line, reduce debt, move on to a new growth future.
Carefully Does It
17 Oct 2016
Dust No idea how long it will take to really digest the stock that hit the market but revisit of the lows very possible or even sub 30p if the market takes a hit or something else is exposed.Mistakes like this like company as they are indicative of lax procedure. Be on guard for anything else lurking in the woodpile.
pharmaspecialist
04 Oct 2016
Re: '...materially below... Unfortunately my suggestion of 19th January to avoid this company was justified and it will be interesting to see if there is anything in the company worth saving. Notice how the "Business Highlights" section of the results press release fails to provide any financial information. One wonders how significant these highlights are. At least the company appears to have recognised that it is a basket case so with a bit luck it will survive.
WAAA
04 Oct 2016
Re: '...materially below... These were the most pathetically unprofessional set of accounts I've read in my life. The kind of thing I'd produce for A level, night before homework had to be in. What a buffoon this ceo/cfo he is. Few weeks ago we were told it was all ok. Now for most of the time the accounts paint a rosy picture, growth in all 3 divisions etc. In the next breath same it's all gone pear shaped. For its worth, I think the 50% drop was a gross overreaction. This is still a profitable, cash generative business. Apparently, we are I advanced stage of appointing a decent ceo and strengthening the board with some pharma experienced non - exec. I suspect the decks are being cleared for the new guy so we are kitchen sinking. Expect see some significant claw back in price as the dust settles.
Blanketstacker
04 Oct 2016
'...materially below... ...market expectations' is the phrase hidden away at the end of the half year results statement today. The result has been a 50% drop in the price here, giving a price of a third of that at the IPO a year ago. This is the second profit warning, and there may well be the ominious third to come. This is all the more frustrating because of the 'in line' statement in July. So what has happened?The big problem seems to be the acquisition last year of NuPharm for c£10m. They provided testing and pharmaceutical manufacturing. It is now being dumped as lossmaking. So we will loose the potential NuPharm revenue, as well as the purchase monies. Not good!!!!BUT we still have the £35m banking facility with RBS. Hopefully this should prevent any need for a fundraising, and the decision has been made to return to the (profitable) core activity of sourcing and provision. The CEO responsible for the disaster has already departed.If profit halves, as has the price, we should still see £900k come in. That should service the very large debt. Any dividend is history.If we side with hope over experience, this could be a decent recovery punt sub-35,which is where it is now. Better still is the potential at under 30. Any opinions please?
gretel
08 Sep 2016
Good news re MED2002 from FUM Great announcement from FUM yesterday regarding MED2002.QP have an exclusive Licensing Agreement with Futura Medical plc. Presumably QP will be selling this product as a special until MED2002 obtains its licence:"Quantum Pharma Plc (AIM: QP.), the growing service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, today announces that it has signed an exclusive agreement with Futura Medical plc (AIM: FUM) the healthcare company which is focused on advanced transdermal technology, to manufacture and make available MED2002, Futura's novel treatment for erectile dysfunction, as an unlicensed medicine (special) in the UK (the "Agreement"
.Under the terms of the Agreement, Quantum has been granted exclusive rights to manufacture and supply MED2002 as a special in the UK. In return Quantum will pay to Futura undisclosed royalty payments on the sale of the product."
Sambram
10 Aug 2016
nice product update "The successful launch of a licensed version of Glycopyrronium Bromide 1mg/5ml oral solution is an important milestone for Quantum and represents a typical, if relatively large, example of the core unlicensed-to-licensed strategy of the group. We will follow its commercialisation progress keenly as success will provide a key validation of this strategy and the inherent value of the pipeline. We make no changes to our forecasts at this stage, but it is reassuring to see the pipeline starting to deliver in line with the expected timetable. Success here and with future launches is likely to drive a substantial re-rating of the shares." - Singers"Quantum Pharma plc, the service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has announced today that Colonis, part of the Niche Pharmaceuticals division, has launched the first licensed glycopyrronium bromide 1mg/5ml oral solution. This is the first licensed version of this product to be made available in the UK and its launch is being driven by ‘cease and desist’ notices to suppliers and manufacturers of equivalent unlicensed products. We are encouraged by this launch as this is the first ‘homegrown’ Niche Pharma registered product which has been licensed since the company made operational changes to address delays in obtaining regulatory approvals." - Zeus CapitalTaken from ResearchTree
Sambram
05 Aug 2016
Mucodis Cream, 5th prod launch Brokers Zeus Capital and N1 Singer covered the announcement in reports published this morning.Singer welcomed it, saying that the range was pitched competitively for the NHS, and whilst it was still in the early stages of its roll-out, the initial response had been positive from patients and clinical teams. Zeus analyst Gary Waanders confirmed that their forecasts remain unchanged after today's news, but said his firm looked forward to seeing strong adoption of the Mucodis range supported by Quantum's dedicated specialist sales team visiting oncologists, pharmacists, and nurses:"We believe that the Mucodis® range has the potential to address a significant proportion of the 350,000 newly diagnosed cancer patients in the UK each year, easing treatment-related side effects and improving quality-of-life."Taken from Research Tree.QP said: "Approximately 352,000 patients in the UK are diagnosed annually with cancer and many experience painful or unpleasant side effects as they progress with their treatment. The Mucodis® range provides the NHS with prescribable products to address a number of the side effects associated with cancer treatments including mucositis, radiation-induced dermatitis, vulvovaginitis and proctitis..." CEO and CFO Chris Rigg:"Whilst it is relatively early following the launch of the range... the initial response from clinical teams at hospitals has been encouraging, and the use in their units has provided favourable patient feedback. We are positive on the outlook for the range over the short to medium term."
Blanketstacker
15 Jul 2016
internal vote of confidence? Company employs 416 bodies. 183 have taken up SAYE options.PER = 9.6PEG = 0.38Yield = c2.2%EPS = 4.5p'Confident' outlook statement in MayRecent increase in holding by Slater Investments.Worth a go?
Simbrad
27 Jun 2016
"The long awaited launch of Ergocalciferol 50,000 IU capsules completes Quantum’s Vitamin D range, meaning the company can offer four different strengths of licensed products addressing both treatment for acute deficiency and maintenance regimes. It is also another unlicensed to licensed development, demonstrating the pipeline is beginning to deliver. The shares have begun to rally in recent days, but still represent good value on under 10x P/E. Next expected news is the prelims on 10th May, when we will revisit our forecasts in detail." Broker note from Singers out this morning on research tree..
Simbr
01 Jun 2016
Re: Biodose Connect Got this from Research Tree this morning, it's by Zeus Capital.. "Improving medication adherence through the use of a system such as Biodose – now extended to include real-time remote monitoring using Biodose Connect® – is expected to have significant positive impacts both on the health of patients and on lowering the overall costs of health care. With its new regulatory status as a CE Marked class I medical device and a measured commercial launch being initiated, we believe that in time Biodose Connect® could generate strong commercial returns for Quantum."
Simbr
01 Jun 2016
Biodose Connect Biodose Connect is a great product, that should do well for Quantum.Andrew Scaife, Chief Executive of Quantum Pharma Plc, commented: "We are delighted that our Biodose Connect® device now has Class I medical device status and we can start to commercialise it. It is an exciting product that we believe will provide a huge benefit to the NHS, social care providers and pharmaceutical companies, not only by reducing the burden created by medication non-adherence, but also in allowing patients to be treated at home. We look forward to bringing Biodose Connect® to the market and showcasing its strong benefits."
Simbrad
01 Jun 2016
"Quantum Pharma plc, the service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has announced today that Biodose Connect® has received Class I medical device status from the MHRA (meaning it now has CE Mark authorisation). Biodose Connect® remotely monitors the use of Quantum’s Biodose trays (each of which holds 28 individually sealed medicine pods) and will assist patients, their carers and clinicians to ensure that medications are being taken as prescribed..." - from a note out this morning by Zeus, it's on Research Tree
gretel
16 May 2016
Slater buying more, above 3% now Great to see Mark Slater taking a 3%+ stake here. Hopefully back to 85p-90p soon for starters:[link]
